Safety of daptomycin in patients receiving hemodialysis

Pharmacotherapy

Volumn 31, Issue 7, 2011, Pages 665-672

  Mueller, Bruce A ^a   Crompton, Jason A ^b   Donovan, Brian J ^b   Yankalev, Sara ^b   Lamp, Kenneth C ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Antibiotics; Daptomycin; Gram positive infection; Hemodialysis; Staphylococcus aureus; Vancomycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; DAPTOMYCIN; LINEZOLID; METICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BONE INFECTION; CARDIOPULMONARY INSUFFICIENCY; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DATA ANALYSIS; DEVICE INFECTION; DIARRHEA; DISEASE REGISTRY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOCCUS FAECIUM; EOSINOPHILIA; FEMALE; FEVER; GRAM POSITIVE INFECTION; HEART ARREST; HEMODIALYSIS; HOSPITAL CARE; HUMAN; HYPONATREMIA; HYPOTENSION; INFECTIOUS ARTHRITIS; INTENSIVE CARE; KIDNEY FAILURE; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PANCYTOPENIA; PSEUDOMONAS INFECTION; PYELONEPHRITIS; RASH; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TEACHING HOSPITAL; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION; URTICARIA; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AGED; ANTI-BACTERIAL AGENTS; CREATINE KINASE; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 79959752340     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.7.665     Document Type: Article

References (27)

1. Himmelfarb J. Hemodialysis complications. Am J Kidney Dis 2005;45:1122-31. (Pubitemid 40806528)
2. Foley RN. Infections in patients with chronic kidney disease. Infect Dis Clin North Am 2007;21:659-72. (Pubitemid 47362601)
3. Berman SJ, Johnson EW, Nakatsu C, Alkan M, Chen R, LeDuc J. Burden of infection in patients with end-stage renal disease requiring long-term dialysis. Clin Infect Dis 2004;39:1747-53. (Pubitemid 39657251)
4. U.S. Centers for Disease Control and Prevention. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients: United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56:197-9.
5. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006;42(suppl 1):S35-9.
6. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44.
7. MacLayton DO, Suda KJ, Coval KA, York CB, Garey KW. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/ml and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006;28:1208-16. (Pubitemid 44374748)
8. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402. (Pubitemid 38747480)
9. U.S. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
10. Dawn M, Sievert DM, Rudrik JT, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-74.
11. Malani PN, Rana MM, Banerjee M, Bradley SF. Staphylococcus aureus bloodstream infections: the association between age and mortality and functional status. J Am Geriatr Soc 2008;56:1485-9
12. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002;162:2229-35. (Pubitemid 35231593)
13. Kang CI, Song JH, Ko KS, Chung DR, Peck KR, for the Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group. Clinical features and outcome of Staphylococcus aureus infection in elderly versus younger adult patients. Int J Infect Dis 2011;15:e58-62.
14. Mascio CTM, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007;51:4255-60. (Pubitemid 350209874)
15. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients Int J Infect Dis 2009;13:291-5.
16. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81. (Pubitemid 38781657)
17. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
18. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004;48:2799-807. (Pubitemid 38989139)
19. Salama NH, Segal JH, Churchwell MD, et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol 2009;4:1190-4.
20. Cubist Pharmaceuticals. Cubicin (daptomycin for injection) full prescribing information. Available from http://www.cubicin. com/pdf/ PrescribingInformation.pdf. Accessed December 17, 2010.
21. Rolston KVI, Segreti J, Lamp KC, Friedrich LV. Cubicin outcomes registry and experience (CORE) methodology. Am J Med 2007;120(10A):S4-5.
22. U.S. Food and Drug Administration. Guideline for industry, clinical safety data management: definitions and standards for expedited reporting. Available from http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM073087.pdf. Accessed December 17, 2010.
23. Weis F, Beiras-Fernandez A, Schelling G. Daptomycin, a lipopeptide antibiotic in clinical practice. Curr Opin Investig Drugs 2008;9:879-84.
24. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010;50:1568-74.
25. Cubist Pharmaceuticals, Inc. Prospective multicenter randomized evaluator-blinded comparator-controlled study to describe the safety and efficacy of daptomycin for the treatment of CSSSI and Staphylococcus aureus bacteremia among subjects with renal impairment. ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinical trials.gov/show/NCT01104662. Accessed August 10, 2010.
26. Allon M, Radeva M, Bailey J, et al. The spectrum of infection-related morbidity in hospitalized haemodialysis patients. Nephrol Dial Transplant 2005;20:1180-6. (Pubitemid 40862108)
27. Decker BS, Mueller BA, Sowinski KM. Drug dosing considerations in alternative hemodialysis. Adv Chronic Kidney Dis 2007;14:e17-26.